Pulsenmore Ltd. began commercial operations in the US following FDA authorization for its home ultrasound platform, signing key agreements and recording its first patient scan in early 2026. The company reported a 53% revenue increase to approximately $2 million in the first half of 2026, driven by higher sales and strategic partnerships, including a collaboration to expand remote prenatal care access. Despite increased operating expenses and a net loss of $11.8 million, Pulsenmore is investing in manufacturing expansion and AI technology grants to support future growth. Management aims to scale US operations and convert early progress into revenue growth in the coming months.
An arbitrator ruled in August 2025 that Gemini did not mislead users or neglect due diligence in its Earn lending program, which collapsed after its partner Genesis Global Capital faced a liquidity crisis. The claim was filed by an Earn user in late ...
RedHill Biopharma has sold its 70% stake in Talicia to Apotex Health Corp. for an upfront payment of $18 million and up to $35 million in potential sales milestones. This deal strengthens RedHill's liquidity and funds its commercial expansion plans, ...
The Franklin FTSE South Korea ETF (FLKR), a top international ETF performer especially after its 2026 breakout, has seen its previous valuation discount to emerging markets close. This removes a key bullish factor for the ETF. South Korea's equity ma...
Eli Lilly's Phase 3b trials show that combining Taltz (ixekizumab) and Zepbound (tirzepatide) maintains or improves psoriasis and psoriatic arthritis outcomes at 52 weeks compared to Taltz alone in patients with obesity. The combo also sustains benef...
Labcorp has enhanced its Global Trial Connect platform, improving digital tools for clinical trial sponsors and investigator sites. The update offers a more intuitive interface, streamlined study management, integrated kit ordering, and a unified das...
